Abstract:Potential conflict of interest: Nothing to report. To the Editor: We read with great interest the article by Bessho et al., who demonstrated that, among the 15 genes uniquely expressed in the liver of patients with biliary atresia (BA), IL8 and LAMC2 were sufficient to distinguish subjects with BA from patients with non‐BA controls, with an accuracy of 95%.1 They conclude that hepatic expression of these two genes may serve as a biomarker of disease. Whereas we appreciate the findings, we would like to address a few issues that may help further clarify or confirm the findings. First, only 14 patients were included as non‐BA controls; the causes of disease were unknown for 64.3% (n = 9) (Supporting Table 1 of Bessho et al.). Moreover, 21.4% (n = 3) of the non‐BA controls were misclassified by IL8 and LAMC2 as BA (Supporting Table 2 of Bessho et al.). It is conceivable that some non‐BA diseases share a similar genetic signature or phenotypic traits with BA, and exhibit similar hepatic expression profiles. Indeed, as previously demonstrated, the IL‐8 level is higher in the BA and non‐BA groups than in normal controls, and the increased IL‐8 level is associated with the lymphocytic count and the degree of fibrosis in BA.2 Also, it has been known that viral infection can promote IL‐8 expression in the liver, which is associated with chronic liver disease.5 Thus, subjects with virus infection in the non‐BA groups might have a similar level of hepatic IL‐8 expression, compared with those in the BA group. In the present study, whether the false positivity by IL8 and LAMC2 observed in three patients in the non‐BA group was associated with infections with viruses such as rotavirus, cytomegalovirus, etc. is unknown. Second, it has been reported that IL‐8 mRNA increases in the liver, particularly in the late stage of BA (e.g., the degree of fibrosis represented by aspartate aminotransferase‐to‐platelet ratio index) and advanced age, and is associated with persistent jaundice, portal hypertension, and/or an increased inflammation and fibrosis in the liver.3 Thus, it is recommended that the patients included in the study be divided into different groups according to the degree of fibrosis (e.g., aspartate aminotransferase‐to‐platelet ratio index) and age (e.g., ≤60, 61‐90, and > 90days). Therefore, it would be interesting if Bessho et al. were to reassess their data by taking viral infection, the degree of fibrosis, and age into account. Alternatively, a larger case‐controlled study incorporating the above‐mentioned points is required.

Analysis of Autoimmune Liver Disease-Associated Antibodies in Infants with Biliary Atresia

The Aberrant Expression of HLA-DR in Intrahepatic Bile Ducts in Patients with Biliary Atresia: an Immunohistochemistry and Immune Electron Microscopy Study.

Immune Characteristics in Biliary Atresia Based on Immune Genes and Immune Cell Infiltration

Unique Cholangiocyte‐Targeted IgM Autoantibodies Correlate With Poor Outcome in Biliary Atresia

Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia

Altered T-Cell Receptor β-Chain and Lactate Dehydrogenase Are Associated With the Immune Pathogenesis of Biliary Atresia

Metabonomics Reveals Metabolite Changes in Biliary Atresia Infants

Expression of programmed death-1 and its ligands in the liver of biliary atresia

Upregulation of High Mobility Group Box 1 May Contribute to the Pathogenesis of Biliary Atresia.

Elevated Bile Acids In Newborns With Biliary Atresia (Ba)

Key Histopathologic Features of Liver Biopsies That Distinguish Biliary Atresia From Other Causes of Infantile Cholestasis and Their Correlation With Outcome: A Multicenter Study

Hepatic Expression of Interleukin 8 in Diagnosing Biliary Atresia

Diagnostic Significance of Autoantibodies in Patients with Primary Biliary Cirrhosis

Distinct Plasma Bile Acid Profiles of Biliary Atresia and Neonatal Hepatitis Syndrome

Comprehensive Analysis of Gut Microbiota and Fecal Bile Acid Profiles in Children With Biliary Atresia

Progress in Biomarkers Related to Biliary Atresia

Bile Acids Impair Vaccine Response in Children with Biliary Atresia

Detection of Autoantibodies in Chronic Liver Disease and Its Correlation with Autoimmune Liver Diseases

Detection of autoantibodies in liver diseases and its clinical application

Autoantibodies profile in autoimmune liver diseases and chronic viral hepatitis

Autoantibodies detection in autoimmune liver disease patients